Previous Article | Next Article ![]()
Journal of Clinical Microbiology, May 1999, p. 1335-1339, Vol. 37, No. 5
Max von Pettenkofer-Institut, Munich, Germany
Received 20 October 1998/Returned for modification 28 December
1998/Accepted 7 February 1999
We present a PCR procedure for identification of Burkholderia
cepacia, Burkholderia multivorans, and
Burkholderia vietnamiensis. 16S and 23S ribosomal DNAs
(rDNAs) of B. multivorans and B. vietnamiensis were sequenced and aligned with published sequences for definition of
species-specific 18-mer oligonucleotide primers. Specific antisense 16S
rDNA primers (for B. cepacia, 5'-AGC ACT CCC RCC TCT
CAG-3'; for B. multivorans, 5'-AGC ACT CCC GAA TCT CTT-3')
and 23S rDNA primers (for B. vietnamiensis, 5'-TCC TAC CAT
GCG TGC AA-3') were paired with a general sense primer of 16S rDNAs
(5'-AGR GTT YGA TYM TGG CTC AG-3') or with a sense primer of 23S rDNA
(5'-CCT TTG GGT CAT CCT GGA-3'). PCR with these primers under optimized conditions is appropriate to specifically and rapidly identify B. multivorans, B. vietnamiensis, and B. cepacia (genomovars I, III, and IV are not discriminated). In
comparison with the polyphasic taxonomic analyses presently necessary
for species and genomovar identification within the B. cepacia complex, our procedure is more rapid and easier to
perform and may contribute to clarifying the clinical significance of
individual members of the complex in cystic fibrosis.
The spectrum of pathogens isolated
from respiratory specimens of cystic fibrosis (CF) patients has changed
within the last 60 years (1). The prevalence of
Pseudomonas aeruginosa has increased, in contrast with that
of Staphylococcus aureus (18). Furthermore, new
species have emerged, e.g., Burkholderia
(Pseudomonas) cepacia, which was first detected
in CF patients in about 1971 (20). The prevalence of
B. cepacia was 7.1% among 283 patients at CF centers in
Munich, Germany, between 1987 and 1997 (4) and 5.6% among
180 patients of the CF centers at the University Clinic in Essen,
Germany, between 1993 and 1998 (8). Govan et al.
(15) reported a prevalence of 7% in Scotland in 1992. An
average prevalence of 3.6% was reported for patients from 113 Cystic
Fibrosis Foundation-accredited centers in the United States by S. FitzSimmons (11a).
Since 1984 (20), it has been known that CF patients who
acquire B. cepacia may follow one of three different
clinical courses: persistent colonization without additional
deterioration of lung function, significantly accelerated reduction of
lung function, or Provided that the incoming Burkholderia strain strongly
determines the further course of CF lung infection, the strains
isolated from patients who develop the "cepacia syndrome" may be
different from strains of CF patients without rapid clinical decline.
So far, all Burkholderia isolates collected from CF patients
were uniformly identified by conventional methods to be B. cepacia and did not appear to be heterogeneous. Thus, it was not
possible to correlate the heterogeneity in the clinical course with a
specific Burkholderia subgroup. This is, however, of major
importance for the individual patient and for the community of persons
with CF.
In fact, Vandamme et al. (31) reidentified 128 isolates
conventionally characterized as B. cepacia by DNA-DNA and
DNA-ribosomal DNA (rDNA) hybridization, assimilation of organic carbon
sources, whole-cell protein pattern, and fatty acid profile. They
subclassified the strains into five species, namely B. vietnamiensis (genomovar V), B. multivorans (genomovar
II), and the B. cepacia genomovars I, III, and IV (these
have no names, as their identification by phenotypic markers is
inconclusive so far). Strains of B. vietnamiensis (14), B. multivorans (8), and the
B. cepacia genomovars I, III, and IV (31) have
been detected in respiratory specimens of CF patients. This
subclassification of strains previously identified as B. cepacia stimulated the advancement of the hypothesis that the
nature of the incoming Burkholderia strain determines or
strongly influences the clinical course of CF lung disease. It has been difficult to evaluate this hypothesis because appropriate procedures for reliable and rapid identification of the Burkholderia
species and genomovars have not been available. There are, however,
reports suggesting that B. cepacia genomovar III strains
were predominantly associated with outbreaks in North America and
Europe (24a, 33). This underlines the importance of accurate
genomovar identification.
Currently, the B. cepacia genomovars I, III, and IV,
B. multivorans, and B. vietnamiensis can be
discriminated by the procedures used for their description (see above).
These procedures are not suitable for routine diagnostic work. Instead,
a number of biochemical reactions were proposed for phenotypic
differentiation (9, 14, 21, 31); however, not all strains
can be reliably identified, e.g., nonsaccharolytic strains (for
example, biovar C of B. cepacia genomovar III), and the
evaluation of the tests may take 3 to 5 days for metabolically
deficient, slow-growing strains. We therefore tried to find a procedure
for specific identification of Burkholderia spp. based on
the diversity within the nucleotide sequences of their 16S and 23S
rDNAs. Sequence motifs characteristic for single species were
integrated into oligonucleotide primers. They allow the production of
PCR products specific for B. multivorans, B. vietnamiensis, and the B. cepacia genomovars I, III,
and IV. Thus, PCR-based molecular procedures to discriminate the
Burkholderia species relevant in CF, including
Burkholderia gladioli (6), are now available.
Organisms.
For characterization of the strains used in this
study, see Table 1.
Nucleic acid preparation.
Genomic DNA was prepared and
purified by using the QiaAmp purification kit (Qiagen, Hilden, Germany).
PCR. (i) For sequencing of the PCR products.
Custom
oligonucleotide primers (see Table 2) were purchased from MWG Biotech,
Ebersberg, Germany. Amplification reactions were carried out in a
50-µl final volume with 1 U of proofreading Taq polymerase
provided with the Expand High Fidelity PCR System (Boehringer,
Mannheim, Germany), 5 µl of the reaction buffer supplied by the
manufacturer (diluted 1:10), 10 µmol of each deoxynucleotide triphosphate, and 50 pmol of each oligonucleotide primer. Approximately 50 to 100 ng of DNA was used as a template. The PCR was carried out in
a GeneAmp PCR system 9600 (Applied Biosystems, Weiterstadt, Germany)
under the following conditions: denaturation for 5 min at 95°C,
followed by 30 amplification cycles of 30 s at 95°C, 30 s
at the annealing temperature specific for the primer, and 45 s at
72°C. The samples were then incubated at 72°C for 7 additional min
and cooled to 4°C. Pyrogen-free water that had been shown to be free
of contaminating DNA was used throughout the study. To inactivate
contaminating DNA, the PCR mixture was exposed to UV light for 15 min
prior to addition of enzyme and template. To ascertain reproducibility,
all species identifications by PCR were performed in duplicate,
starting each time from new cultures. The amplification products were
checked by agarose gel electrophoresis and purified of salt and excess
primers by using the PCR purification kit (Qiagen).
(ii) For identification of unknown strains.
The same
procedure as described above was followed, with some exceptions: half
of the volumes of all amplifications reagents was used, and normal
Taq polymerase was used instead of the proofreading Taq of the High Fidelity PCR System. For each reaction, a
specific antisense primer was combined with the universal sense primer Eub-16-1, and for identification of B. vietnamiensis the
primers ViMaPs-23-1 and CeVi-23-2 were used (Table 3).
Agarose gel electrophoresis.
Agarose gel electrophoresis was
performed as described previously (5).
Sequence determination.
The amplified rDNAs were sequenced
as described previously (23). The two strands of the DNA
were sequenced from different PCR products. A model 373A DNA Sequencer
(Applied Biosystems) was used, following the protocol of the
manufacturer for dye terminator reactions.
Analysis of the sequence data.
The nucleotide sequences were
aligned with reference rDNA sequences provided in the noncommercial
software program package ARB (beta-version 2.4). Secondary structure
analysis was done according to the method of Ludwig et al.
(24).
Nucleotide sequence accession numbers.
The 16S and 23S
rDNA sequences of B. multivorans (B. cepacia
genomovar II) LMG 13010T and the 23S rDNA sequence of
B. vietnamiensis (B. cepacia genomovar V) LMG
10929T have been deposited in the EMBL database under the
accession nos. 418703, 418704, and 418705.
Analysis of 16S and 23S rDNA sequences.
16S rDNA sequences of
B. cepacia were found in the literature (24). We
sequenced 16S rDNA of reference strains (Table
1) of B. multivorans and
B. vietnamiensis and of the B. cepacia genomovars I and III kindly supplied to us by P. A. R. Vandamme (Gent,
Belgium). Multiple alignment of the sequences of various strains
demonstrated among the species substitutions of nucleotides included
within the variable helix 18 or 37/38 regions. They were used for the definition of species-specific primers (Table
2). No sequences appropriate for
discrimination between B. multivorans and B. vietnamiensis were detectable in the 16S rDNA. However, analysis
of the 23S rDNA revealed sites with nucleotides that were different
from those in the other Burkholderia spp. included but were
identical in the four B. vietnamiensis strains investigated.
Thus, as shown for differentiation of Burkholderia mallei
and Burkholderia pseudomallei (5), the 23S rDNA
sequences may be useful when no suitable nucleotide substitutions are
detectable in the 16S rDNA genes.
0095-1137/99/$04.00+0
Discrimination of Burkholderia
multivorans and Burkholderia vietnamiensis from
Burkholderia cepacia Genomovars I, III, and IV by
PCR
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
in about 20% of the patients
rapid deterioration
with signs and symptoms of acute necrotic pneumonia with or without
septicemia and fatal outcome within several weeks or months ("cepacia
syndrome" [20]). The factors which determine this
dissociation may be either pathogen- or patient-related, or both.
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TABLE 1.
Investigated strains
TABLE 2.
Primers selected for PCR
Specificity of PCR.
Primers were combined to form pairs and
were used to establish optimal conditions for specificity. Each pair of
opposite primers was analyzed for the specificity in comparison with
those of all other Burkholderia species or genomovars and of
Ralstonia pickettii. No amplification products were detected
with heterologous Burkholderia strains (Table
3). Furthermore, we studied
representative strains of species which grow on tryptone soya agar
supplemented with 16 µg of colistin/ml. Two strains each of the
following species were included: Proteus mirabilis,
Morganella morganii, Serratia liquefaciens,
Alcaligenes xylosoxidans, Stenotrophomonas
maltophilia, Brevundimonas diminuta, and P. aeruginosa (MIC of colistin, >64 µg/ml). In addition, strains
assumed to be Burkholderia spp. were sent to us for
verification. Some of them were negative according to our PCR
procedure, so they were subjected to conventional identification reactions. They proved to be A. xylosoxidans (n = 15), P. aeruginosa (n = 10), S. maltophilia (n = 6), M. morganii
(n = 3), and Citrobacter freundii
(n = 3). The results were definitive, and no
amplification products obtained with any of the specific primer pairs
shown in Table 3 were detectable with templates of these strains.
|
Procedure for identification of Burkholderia spp. For identification of strains shown to be Burkholderia spp. by API 20NE, four separate PCRs are run. They included primers of different degrees of specificity in order to achieve stepwise exclusion of single species: Bu-Ra excludes species of genera other than Burkholderia or Ralstonia, CeMuVi-16-2457 excludes B. gladioli and Ralstonia spp., MuVi-16-21028 excludes B. cepacia, and the 23S rDNA primers specific for B. vietnamiensis exclude B. multivorans. Except for B. cepacia, which includes the three genomovars I, III, and IV, all species can be identified by positive reactions (B. vietnamiensis, B. gladioli, and R. pickettii) or exclusion (B. multivorans). For the B. cepacia genomovars I, III, and IV, no specific signatures were found within 16S or 23S rDNA sequences. Strains yielding products of PCR with the Bu-Ra primers but negative for PCR with the other primers may be either B. mallei or B. pseudomallei. They can be identified as described previously (5).
Evaluation of the primers with CF isolates. We studied 124 isolates collected from CF patients from four European countries. They had been identified by conventional phenotypic means as B. cepacia and collected for PCR. All of the strains could be classified. Of the isolates 79 (63.7%) were found to be B. multivorans, 42 (33.9%) were B. cepacia, 2 (1.6%) were B. gladioli (Hannover, Germany), and 1 (0.8%) was B. vietnamiensis (Amsterdam, The Netherlands). B. multivorans appears to be the dominating species among Burkholderia isolates from European CF centers investigated in this work (7). No major spread of B. multivorans strains was observed among 10 patients of one CF center. Altogether, eight different randomly amplified polymorphic DNA types were identified, and only two of them were detected in more than one patient (8).
| |
DISCUSSION |
|---|
|
|
|---|
In CF, the basic genetic defect predisposes the individual to lung infections caused by specific bacterial pathogens. The major gram-negative organisms causing chronic recurrent lung inflammation are P. aeruginosa and Burkholderia spp. Once established, these pathogens can be eradicated only infrequently and transiently. Nevertheless, the increase in life expectancy and quality of life achieved within the last decade is mainly attributed to progress in antiinfective therapy. Therefore, even transient reduction in the concentration of pathogens at the site of infection benefits the clinical status and prognosis of the patient. As long as gene therapy is not available antimicrobial treatment must be optimized, along with measures for the prevention of early infection and the transmission of pathogens among CF patients.
These measures rely on the knowledge of the microbiological status of the CF patient at all times. Exact data on the identity of the pathogens and their concentrations in respiratory secretions (mostly sputum) as well as on their susceptibility to therapeutically relevant antibiotics allow the rational design of treatment regimens and effective strategies for controlling the spread of these pathogens from infected to pathogen-free patients.
At this time, the genus Burkholderia is thought to be composed of 16 species (10, 32, 36). Most of these are primarily plant pathogens; the CF-relevant Burkholderia species are restricted to B. cepacia (genomovars I, III, and IV), B. multivorans, B. gladioli, and B. vietnamiensis. Their detection in diagnostic laboratories depends initially on the use of selective media which inhibit growth of P. aeruginosa. All Burkholderia spp. of potential relevance in CF lung disease grow on colistin-supplemented media (12, 17, 19, 34). In a quality control trial carried out by Tablan et al. (30), only 32% of the participating 115 laboratories detected B. cepacia in the test sputum. In a surveillance study including 78 centers in Germany conducted in 1997, the prevalence of Burkholderia spp. was 4.1% when a selective medium containing colistin was used but only 1.8% when selective medium was not used (our own unpublished data). In fact, only about one-fifth of the sputa were analyzed by using a Burkholderia-selective agar. On colistin-containing media, besides Burkholderia spp., a variety of other species are able to grow (e.g., Proteus spp., Providencia spp., M. morganii, Serratia spp., A. xylosoxidans, and staphylococci).
For identification of Burkholderia spp., the procedures used for their taxonomic description (13, 28) (see Introduction) are inappropriate in clinical laboratories. The aim of our work was to establish procedures which meet the demands of clinical practice where determination of both the identity of a pathogen and its antibiotic susceptibility is called for. For this purpose, culturing of the organisms is indispensable. Thus, our identification procedure is based on culture. The procedure may also be adapted to detect Burkholderia spp. in situ, e.g., in sputum specimens. The major advantage of the PCR-based identification is rapidity. While evaluation of the biochemical reactions proposed for phenotypic differentiation (9, 14, 21, 31) may take up to 7 days (17), the PCR procedure is performed within 5 h. The biochemical tests for reliable identification are not commercially available now and have to be prepared and controlled for quality within individual laboratories. They are inappropriate for the identification of nonsaccharolytic strains (e.g., biovar C of B. cepacia genomovar III [31]).
Molecular identification of pathogens relies on the diversity of the nucleotide sequences of the 16S and 23S rDNA sequences with specific motifs conserved at different phylogenetic levels, e.g., genus and species. This diversity has been used for species-specific PCR procedures (22, 26, 28). Our 16S and 23S rDNA sequence data for B. vietnamiensis, B. multivorans, and the B. cepacia genomovars I, III, and IV demonstrated options for discriminatory primers. Among them, the oligonucleotides listed in Table 2 were found to be appropriate for the identification of B. multivorans, B. vietnamiensis, and the B. cepacia genomovars I, III, and IV, which could not be separated until now. The different PCRs may be run separately to discriminate simultaneously B. cepacia (genomovars I, III and IV are included), B. multivorans, or B. vietnamiensis from colonies identified conventionally as a Burkholderia species. A mixture from different colonies (instead of a pure culture) should be tested to find out whether the specimen contains more than one species.
A molecular identification procedure for B. cepacia that uses 16S rDNA sequences was proposed by Campbell et al. (11). This work preceded the changes of taxonomy in 1997 (31) and therefore could not include efforts to differentiate the five B. cepacia complex genomovars. Analysis of the primers described by Campbell et al. demonstrated specificity for B. cepacia. No PCR products were amplified from DNA templates of B. multivorans and B. vietnamiensis (our own unpublished data), while discrimination of B. gladioli had already been shown by the authors. Whitby et al. (35), in addition to the primers described by Campbell et al. (11), used a primer pair, G-1 and G-2, targeting the 130-bp spacer region between 16S and 23S rDNA. However, the spacer-directed primers were less specific than the 16S-rDNA-derived primers. The PCR procedures which we present facilitate rapid and specific identification of B. multivorans, B. vietnamiensis, B. gladioli (6), and B. cepacia. However, the primers proposed for identification of B. cepacia do not discriminate among the B. cepacia genomovars I, III, and IV. Work for molecular differentiation of these genomospecies is in progress.
The basic question has been asked whether members within a genus of mostly phytopathogenic species can be primary causative pathogens in CF or whether they are just indicators of a late stage of lung disease. The pros and cons have been presented and discussed by different authors (13, 16). It is so far uncertain whether among the Burkholderia spp. in CF patients, there are species with increased virulence (25) which on their own or in combination with cofactors (e.g., preceding damage of lung tissue by other microorganisms) cause the rapid clinical deterioration of the patient. Major outbreaks in Canada and the United Kingdom were caused by the spread of particular strains which produce cblA protein (27, 29) and appear to be B. cepacia genomovar III. This may indicate that virulence might be associated with a particular type or species of pathogen and that accurate identification of the species of the B. cepacia complex is of major clinical importance. The PCR-based procedures proposed to discriminate B. cepacia, B. multivorans, B. vietnamiensis, and B. gladioli should help to clarify their prevalence, epidemiology, antibiotic susceptibility, and pathogenetic potential in CF (2, 3).
| |
ACKNOWLEDGMENTS |
|---|
We thank H. Bärmeier, Erlangen, J. Dankert, Amsterdam, L. Möller, Groningen, J. Govan, Edinburgh, N. Høiby, Copenhagen, F. Ratjen and K. Hübner, Essen, D. Speert, Vancouver, and B. Tümmler, Hanover, for providing Burkholderia isolates from their CF patients. We are most grateful to Peter Vandamme, Gent, Belgium, for stimulating discussions and verification of species identification obtained by the PCR-based procedures described.
Part of the work on this project was supported by a grant from the German Ministry of Defense and by the Christiane-Herzog-Stiftung for CF patients, Berlin, Germany.
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Max von Pettenkofer-Institut, Ludwig-Maximilians-Universität München, Pettenkoferstr. 9a, D-80336 München, Germany. Phone: 49-89-5160-5268. Fax: 49-89-5160-5266. E-mail: Adolf.Bauernfeind{at}mvp-bak.med.uni-muenchen.de.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Andersen, D. H.
1938.
Cystic fibrosis of pancreas and its relation to celiac disease: clinical and pathological study.
Am. J. Dis. Child.
56:344-399 |
| 2. | Bauernfeind, A., R. Jungwirth, and I. Schneider. 1998. Comparative susceptibility of Burkholderia cepacia and the new species Burkholderia multivorans to ciprofloxacin, ceftazidime, and meropenem, abstr. E-163, p. 216. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. |
| 3. | Bauernfeind, A., R. Jungwirth, I. Schneider, and F. Ratjen. 1998. Activity of new fluoroquinolones against Burkholderia cepacia and Burkholderia multivorans from cystic fibrosis patients, abstr. 420, p. 322. In 12th Annual North American Cystic Fibrosis Conference, Montreal, Canada. Wiley-Liss, Inc., Somerset, N.J. |
| 4. | Bauernfeind, A., and B. Przyklenk. 1997. Microbiological background for anti-Pseudomonas aeruginosa vaccination in cystic fibrosis. Behring Inst. Mitt. 98:256-261. |
| 5. |
Bauernfeind, A.,
C. Roller,
D. Meyer,
R. Jungwirth, and I. Schneider.
1998.
Molecular procedure for rapid detection of Burkholderia mallei and Burkholderia pseudomallei.
J. Clin. Microbiol.
36:2737-2741 |
| 6. |
Bauernfeind, A.,
I. Schneider,
R. Jungwirth, and C. Roller.
1998.
Discrimination of Burkholderia gladioli from other Burkholderia species detectable in cystic fibrosis patients by PCR.
J. Clin. Microbiol.
36:2748-2751 |
| 7. | Bauernfeind, A., I. Schneider, R. Jungwirth, and C. Roller. 1998. Prevalence of Burkholderia gladioli and Burkholderia vietnamiensis in cystic fibrosis, abstr. 421, p. 322. In 12th Annual North American Cystic Fibrosis Conference, Montreal, Canada. Wiley-Liss, Inc., Somerset, N.J. |
| 8. | Bauernfeind, A., I. Schneider, A. Palm, F. Ratjen, and K. Hübner. 1998. Prevalence and transmission of Burkholderia multivorans among CF patients, abstr. 422, p. 322. In 12th Annual North American Cystic Fibrosis Conference, Montreal, Canada. Wiley-Liss, Inc., Somerset, N.J. |
| 9. |
Baxter, I. A.,
P. A. Lambert, and I. N. Simpson.
1997.
Isolation from clinical sources of Burkholderia cepacia possessing characteristics of Burkholderia gladioli.
J. Antimicrob. Chemother.
39:169-175 |
| 10. |
Brett, P. J.,
D. DeShazer, and D. E. Woods.
1998.
Burkholderia thailandensis sp. nov., a Burkholderia pseudomallei-like species.
Int. J. Syst. Bacteriol.
48:317-320 |
| 11. | Campbell, P. W., III, J. A. Phillips III, G. J. Heidecker, M. R. S. Krishnamani, R. Zahorchak, and T. L. Stull. 1995. Detection of Burkholderia cepacia using PCR. Pediatr. Pulmonol. 20:44-49[Medline]. |
| 11a. | FitzSimmons, S. 1997. US registry and B. cepacia surveillance in the US, p. 2. In Minutes of the 3rd Meeting of the International Burkholderia cepacia Working Group. |
| 12. |
Gilligan, P. H.,
P. A. Gage,
L. M. Bradshaw,
D. V. Schidlow, and B. T. DeCicco.
1985.
Isolation medium for the recovery of Pseudomonas cepacia from respiratory secretions of patients with cystic fibrosis.
J. Clin. Microbiol.
22:5-8 |
| 13. |
Gilligan, P.
1991.
Microbiology of airway disease in patients with cystic fibrosis.
Clin. Microbiol. Rev.
4:35-51 |
| 14. |
Gillis, M.,
T. Van Van,
R. Bardin,
M. Goor,
P. Hebbar,
A. Willems,
P. Segers,
K. Kersters,
T. Heulin, and M. P. Fernandez.
1995.
Polyphasic taxonomy in the genus Burkholderia leading to an emended description of the genus and proposition of Burkholderia vietnamiensis sp. nov. for N2-fixing isolates from rice in Vietnam.
Int. J. Syst. Bacteriol.
45:274-289 |
| 15. | Govan, J. R. W., P. H. Brown, J. Maddison, C. J. Doherty, J. W. Nelson, M. Dodd, A. P. Greening, and A. K. Webb. 1993. Evidence for transmission of Pseudomonas cepacia by social contact in cystic fibrosis. Lancet 342:15-19[Medline]. |
| 16. |
Govan, J. R. W.,
J. E. Hughes, and P. Vandamme.
1996.
Burkholderia cepacia: medical, taxonomic and ecological issues.
J. Med. Microbiol.
45:395-407 |
| 17. | Henry, D. A., M. E. Campbell, J. J. LiPuma, and D. P. Speert. 1997. Identification of Burkholderia cepacia isolates from patients with cystic fibrosis and use of a simple new selective medium. J. Clin. Microbiol. 35:614-619[Abstract]. |
| 18. | Høiby, N. 1982. Microbiology of lung infections in cystic fibrosis. Acta Paediatr. Scand. 1982(Suppl. 301):33-54. |
| 19. | Holmes, B. 1986. The identification of Pseudomonas cepacia and its occurrence in clinical material. J. Appl. Bacteriol. 61:299-314[Medline]. |
| 20. | Isles, A., I. Maclusky, M. Corey, R. Gold, C. Prober, P. Fleming, and H. Levison. 1984. Pseudomonas cepacia in cystic fibrosis: an emerging problem. J. Pediatr. 104:206-210[Medline]. |
| 21. | Kiska, D. L., A. Kerr, M. C. Jones, J. A. Caracciolo, B. Eskridge, M. Jordan, S. Miller, D. Hughes, N. King, and P. H. Gilligan. 1996. Accuracy of four commercial systems for identification of Burkholderia cepacia and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. J. Clin. Microbiol. 34:886-891[Abstract]. |
| 22. |
Lane, D. J.,
B. Pace,
G. J. Olson,
D. A. Stahl,
M. L. Sogin, and N. R. Pace.
1985.
Rapid determination of 16S ribosomal RNA sequences for phylogenetic analysis.
Proc. Natl. Acad. Sci. USA
82:6955-6959 |
| 23. | Ludwig, W., G. Kirchhof, N. Klugbauer, M. Weizenegger, D. Betzl, M. Ehrmann, C. Hertl, S. Jilg, R. Tatzel, H. Zitzelsberger, S. Liebl, M. Hochberger, D. Lane, P. R. Wallnöfer, and K.-H. Schleifer. 1992. Complete 23S ribosomal RNA sequences of Gram-positive bacteria with a low DNA G+C content. Syst. Appl. Microbiol. 15:487-501. |
| 24. | Ludwig, W., R. Rosselló-Mora, R. Aznar, S. Klugbauer, S. Spring, K. Reetz, C. Beimfohr, E. Brockmann, G. Kirchhof, S. Dorn, M. Bachleitner, N. Klugbauer, N. Springer, D. Lane, R. Nietupsky, M. Weizenegger, and K.-H. Schleifer. 1995. Comparative sequence analysis of 23S rRNA from Proteobacteria. Syst. Appl. Microbiol. 18:164-188. |
| 24a. | Mahenthiralingam, E. 1998. Update on Canadian repository, p. 4-5. In Minutes of the 5th Meeting of the International Burkholderia cepacia Working Group. |
| 25. | Nelson, J. W., S. L. Butler, D. Krieg, and J. R. W. Govan. 1994. Virulence factors of Burkholderia cepacia. FEMS Immunol. Med. Microbiol. 8:89-98[Medline]. |
| 26. | Olsen, G. J., G. Larsen, and C. R. Woese. 1991. The ribosomal RNA database project. Nucleic Acids Res. 19(Suppl):2017-2021. |
| 27. |
Sajjan, U. S.,
L. Sun,
R. Goldstein, and J. F. Forstner.
1995.
Cable (Cbl) type II pili of cystic fibrosis-associated Burkholderia (Pseudomonas) cepacia: nucleotide sequence of the cblA major subunit pilin gene and novel morphology of the assembled appendage fibers.
J. Bacteriol.
177:1030-1038 |
| 28. |
Stackebrandt, E., and B. M. Goebel.
1994.
Taxonomic note: a place for DNA-DNA reassociation and 16S rDNA sequence analysis in the present species definition in bacteriology.
Int. J. Syst. Bacteriol.
44:846-849 |
| 29. | Sun, L., R.-Z. Jiang, S. Steinbach, A. Holmes, C. Campanelli, J. Forstner, Y. Tann, M. Riley, and R. Goldstein. 1995. The emergence of a highly transmissible lineage of Cbl+ Pseudomonas (Burkholderia) cepacia causing CF center epidemics in North America and Britain. Nat. Med. 1:661-666[Medline]. |
| 30. |
Tablan, O. C.,
L. A. Carson,
L. B. Cusick,
L. A. Bland,
W. J. Martone, and W. R. Jarvis.
1987.
Laboratory proficiency test results on use of selective media for isolating Burkholderia cepacia from simulated sputum specimens of patients with cystic fibrosis.
J. Clin. Microbiol.
25:485-487 |
| 31. |
Vandamme, P.,
B. Holmes,
M. Vancanneyt,
T. Coenye,
B. Hoste,
R. Coopman,
H. Revets,
S. Lauwers,
M. Gillis,
K. Kersters, and J. R. W. Govan.
1997.
Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov.
Int. J. Syst. Bacteriol.
47:1188-1200 |
| 32. |
Viallard, V.,
I. Poirier,
B. Cournoyer,
J. Haurat,
S. Wiebkin,
K. Ophel-Keller, and J. Balandreau.
1998.
Burkholderia graminis sp. nov., a rhizospheric Burkholderia species, and reassessment of [Pseudomonas] phenazinium, [Pseudomonas] pyrrocinia and [Pseudomonas] glathei as Burkholderia.
Int. J. Syst. Bacteriol.
48:549-563 |
| 33. |
Webb, A. K., and J. R. Govan.
1998.
Burkholderia cepacia: another twist and a further threat.
Thorax
53:333-334 |
| 34. |
Welch, D. F.,
M. J. Muszynski,
C. H. Pai,
M. J. Marcon,
M. M. Hribar,
P. H. Gilligan,
J. M. Matsen,
P. A. Ahlin,
B. C. Hilman, and S. A. Chartrand.
1987.
Selective and differential medium for recovery of Pseudomonas cepacia from the respiratory tracts of patients with cystic fibrosis.
J. Clin. Microbiol.
25:1730-1734 |
| 35. |
Whitby, P. W.,
H. L. N. Dick,
P. W. Campbell III,
D. E. Tullis,
A. Matlow, and T. L. Stull.
1998.
Comparison of culture and PCR for detection of Burkholderia cepacia in sputum samples of patients with cystic fibrosis.
J. Clin. Microbiol.
36:1642-1645 |
| 36. | Yabuuchi, E., Y. Kosako, I. Yano, H. Hotta, and Y. Nishiuchi. 1995. Transfer of two Burkholderia and an Alcaligenes species to Ralstonia gen. nov.: proposal of Ralstonia pickettii (Ralston, Palleroni and Doudoroff 1973) comb. nov., Ralstonia solanacearum (Smith 1896) comb. nov. and Ralstonia eutropha (Davis 1969) comb. nov. Microbiol. Immunol. 39:897-904[Medline]. |
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»